In a phase 2 trial of 71 adults with uncontrolled chronic rhinosinusitis without nasal polyps, dupilumab improved Lund-Mackay CT score at week 24 in the 16 with blood eosinophils ≥300 cells/uL (mean change −6.63); symptom gains vs placebo were not significant.
RCTn = 71
Lee et al. Dupilumab in chronic rhinosinusitis without nasal polyps: randomized phase 2 trial (ORION)